NK01-63 (Coronastat) CAS 2922281-15-8 | SARS-CoV-2 3CL Protease Inhibitor | Nutrabiotech Chem

NK01-63 (Coronastat) CAS 2922281-15-8
SARS-CoV-2 3CL Protease Inhibitor

Name: NK01-63 (Coronastat)
Brand: Nutrabiotech Chem
SKU: NK01-63-2922281-15-8
Price: Inquiry USD
Availability: InStock

NK01-63, also known as Coronastat (CAS 2922281-15-8), is a potent, reversible-covalent inhibitor of the SARS-CoV-2 3CL protease (main protease, Mpro) — a validated antiviral drug target essential for viral polyprotein maturation and replication. It shows high potency (IC50 ~16 nM, EC50 ~6 nM) and a high selectivity index (>10,000). It is a preclinical research compound and an analog of GC376. Formula C22H29F3N3NaO8S, MW 575.53. Research use only.

NK01-63Coronastat3CL ProteaseSARS-CoV-2COVID-19AntiviralGC376 analogMpro

Request a Quote Technical Specs

575.53

MW (C22H29F3N3NaO8S)

16 nM

IC50 (3CLpro)

3CL

Protease target

Molecular Information

Name: NK01-63 (Coronastat)
CAS: 2922281-15-8
Formula: C22H29F3N3NaO8S
MW: 575.53 g/mol
Class: SARS-CoV-2 3CL protease inhibitor
Core: GC376-type aldehyde precursor (Na salt)
Target: SARS-CoV-2 3CL protease (Mpro)
Activity: Reversible covalent inhibition
IC50 / EC50: ~16 nM / ~6 nM
Appearance: White to off-white powder
Synonyms: Coronastat
Storage: -20°C, protect from light

2922281-15-8

🧪

CAS Number

575.53

⚖️

Molecular Weight

3CL Protease

🎯

Primary Activity

≥98%

✅

Purity

Product Technical Specifications

Complete physicochemical properties and QC parameters for NK01-63 (Coronastat, CAS 2922281-15-8)

📋 Physicochemical Properties

Product NameNK01-63 (Coronastat)
CAS Number2922281-15-8
SynonymsCoronastat; GC376 analog
Molecular FormulaC22H29F3N3NaO8S
Molecular Weight575.53 g/mol
SourceSynthetic (small molecule)
AppearanceWhite to off-white powder
Water SolubilitySoluble (sodium salt)
Organic SolubilityDMSO; ethanol
Compound ClassSARS-CoV-2 3CL protease inhibitor
Counter IonSodium (Na) salt
HS Code2934.99

🔬 Quality Control & Handling

Purity (HPLC)≥98%
FormPowder (sodium salt)
Primary TargetSARS-CoV-2 3CL protease (Mpro)
Reported PotencyIC50 ~16 nM; EC50 ~6 nM
SelectivityHigh SI (>10,000) in Huh-7
Storage Condition-20°C, sealed, protect from light
Solution StabilityStock -80°C ~1 yr; -20°C ~1 mo
ShippingCold chain recommended
QC DocumentationCOA / HPLC / NMR / MS / MSDS
Pack Sizes5mg / 10mg / 25mg / 50mg / 100mg
Stock StatusIn Stock
Use StatementResearch use only; not for human use

Key Molecular Targets & Biology Nodes

NK01-63 engages the viral protease machinery that defines its broad-spectrum coronavirus utility.

🧬 SARS-CoV-2 3CL Protease 🧬 3CLpro / Mpro 🧬 Viral polyprotein 🧪 Protease cleavage 💧 Viral replication 🧭 Coronavirus lifecycle 🍃 Antiviral 🔬 Drug discovery 🦠 SARS-CoV-2 🧬 Broad-spectrum CoV

How NK01-63 Works: Shutting Down Viral Protease Activity

NK01-63 targets the main protease, an enzyme no mammalian cell possesses — a key antiviral selectivity advantage.

Binding of the 3CL Protease

NK01-63 binds the SARS-CoV-2 3CL protease (Mpro) in a reversible covalent manner at the enzyme active site, an interaction analogous to its parent GC376.

Blockade of Polyprotein Cleavage

With the protease inhibited, the viral polyprotein cannot be cleaved into the functional non-structural proteins required for genome replication and transcription.

Suppression of Viral Replication

Loss of proteolytic processing halts production of infectious virions, yielding potent antiviral activity (EC50 ~6 nM) with high selectivity over host cells.

⚖️ NK01-63 vs Comparators

NK01-63 (this product)3CL protease inhibitor (GC376 analog)
GC376Parent broad-spectrum 3CL inhibitor
Nirmatrelvir (PF-07321332)Clinically used 3CL inhibitor
RemdesivirViral RNA polymerase (RdRp) inhibitor
Research NicheProtease inhibitor lead / screening

♻️ Downstream Biological Consequences

Enzyme3CL protease blocked
ViralPolyprotein cleavage stopped
ReplicationVirion production down
CytopathyCPE reduced (host spared)
SelectivityHigh SI (>10,000)
ModelsAntiviral / virology assays

Research & Drug-Discovery Applications

NK01-63 is a high-potency chemical probe for coronavirus protease biology and antiviral lead optimization.

🦠

COVID-19 Antiviral Research

Potent probe of SARS-CoV-2 replication and 3CL-protease dependency.

COVID-19

🧬

3CL Protease Assays

Enzyme inhibition, cleavage and biochemical profiling.

3CLpro

🌐

Broad-Spectrum Coronavirus

Lead for pan-coronavirus antiviral development.

Coronavirus

💊

Drug Discovery / SAR

Optimization starting point; GC376 analog chemotype.

SAR

🧪

Virology Screening

Cell-based CPE / plaque-reduction and selectivity screens.

Virology

🔬

Mechanism-of-Action Studies

Reversible-covalent protease inhibition characterization.

MoA

Key Literature & Landmark Publications

Landmark and representative work on NK01-63 / Coronastat and SARS-CoV-2 3CL protease inhibitors.

Liu H, et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 2022;13(1):1891.

Source publication (NK01-63 / Coronastat)

Review. SARS-CoV-2 main protease (Mpro/3CLpro) as an antiviral target.

Landmark reference

Preclinical reports. GC376-type inhibitors in coronavirus models.

Landmark reference

Structural studies. Reversible-covalent inhibition of 3CL protease.

Landmark reference

Comparative studies. 3CL protease vs RdRp antiviral strategies.

Landmark reference

Available Sizes & Ordering

Research-grade NK01-63 (Coronastat, CAS 2922281-15-8) with full QC documentation; standard packs and bulk custom quantities supported.

Tier	Pack Size	Stock Status	Suitable For	Lead Time
Standard	5 mg	In Stock	Enzyme / biochemical assays	Same/next-day ship
Medium	10 mg	In Stock	Cell-based antiviral screens	Same/next-day ship
Large	25 mg	In Stock	In vitro / biochem panels	Same/next-day ship
Bulk	50 mg	In Stock	Lead optimization	Quote to confirm
Industrial	100 mg+	Made to order	Process development	Batch delivery

💡 Reference sizes shown above; for exact pricing and availability please contact us for a quote. Bulk orders qualify for tiered discounts.

Frequently Asked Questions (FAQ)

What is NK01-63 (Coronastat)?

NK01-63, also known as Coronastat (CAS 2922281-15-8), is a potent inhibitor of the SARS-CoV-2 3CL protease (main protease, Mpro). It acts by reversible covalent inhibition of this essential viral enzyme. Formula C22H29F3N3NaO8S, MW 575.53. It is a preclinical research compound and an analog of GC376.

How potent is NK01-63 against SARS-CoV-2?

Reported activity is high: IC50 ~16 nM and EC50 ~6 nM in antiviral assays, with a selectivity index greater than 10,000 (CC50 >100 µM in Huh-7 cells). Exact values are batch-dependent and stated on the COA.

What is the mechanism of NK01-63?

NK01-63 binds the SARS-CoV-2 3CL protease in a reversible covalent manner, blocking cleavage of the viral polyprotein into functional replication proteins and thereby suppressing viral replication.

How soluble is NK01-63 and how should it be prepared?

As a sodium salt, NK01-63 is soluble in DMSO, water and ethanol. Prepare fresh stocks in anhydrous DMSO (or aqueous buffer) and store at -20°C protected from light; avoid repeated freeze-thaw.

Is NK01-63 an approved drug?

No. NK01-63 (Coronastat) is a preclinical research compound and has not entered clinical trials. It is supplied for laboratory research use only and is not intended for human or veterinary administration.

Is QC documentation provided?

Every batch ships with a Certificate of Analysis (COA) including HPLC purity, structural confirmation and MS data; MSDS/SDS and Certificates of Origin are available on request.

Need NK01-63 (Coronastat) for Your Research?

Research-grade NK01-63 (Coronastat, CAS 2922281-15-8) — purity ≥98% HPLC, COA included
SARS-CoV-2 3CL protease inhibitor (IC50 ~16 nM) — request a quote today

Request a Quote →

NK01-63 CAS 2922281-15-8 98% Purity 3CL Protease Inhibitor Powder